Abstract B112: A Dose Escalation and Cohort Expansion Study of the CDK9 Inhibitor KB-0742 in Relapsed, Refractory Ovarian Cancer and Transcriptionally Addicted Relapsed or Refractory Solid Tumors
Cancer Research（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined